Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422330 | 0.84 | LTA4H (0.37) | NQO1TSHRLTA4HRAB9ACA12 | |
| SCHEMBL2115755 | 0.84 | LTA4H (0.44) | TSHRSMN1; SMN2LTA4HNPC1RAB9A | |
| SCHEMBL1983658 | 0.83 | TSHR (0.32) | TSHRMAPT | |
| SCHEMBL1097013 | 0.82 | CA1 (0.44) | TDP1MAPTCA12CA1CA2 | |
| SCHEMBL1919533 | 0.82 | LTA4H (0.43) | TSHRKDM4ELTA4HRAB9ACA12 | |
| SCHEMBL7058830 | 0.80 | LMNA (0.50) | SMN1; SMN2LTA4HL3MBTL1MAPTRAB9A | |
| SCHEMBL6288626 | 0.80 | PLA2G4B (0.50) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4769134 | 0.80 | GAA (0.55) | KDM4EALDH1A1SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL30592117 | 0.79 | NR5A1 (0.50) | TSHRLTA4HNPC1MAPTRAB9A | |
| SCHEMBL7862872 | 0.78 | LTA4H (0.31) | LTA4HNR5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439901-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150065565-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065512-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2496583-B1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8669380-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2496583-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2011051864-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065512-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | NQO1 2731/4885TSHR 2426/4885TDP1 2673/4885 |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | NQO1 2731/4885TSHR 2426/4885TDP1 2673/4885 |
| US-20150065565-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | NQO1 2731/4885TSHR 2426/4885TDP1 2673/4885 |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | NQO1 2731/4885TSHR 2426/4885TDP1 2673/4885 |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | NQO1 2731/4885TSHR 2426/4885TDP1 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.